Noteworthy

Mar 20, 2018
The industry should embrace value assessment developments in the US and take a leading role in defining credible and relevant cost-effectiveness studies, write Ross Maclean and Jeroen Jansen.
Mar 20, 2018
Pharmaceutical Executive
Executives from diagnostics, payer, pharma, and patient care companies converge to share the inside scoop on outcomes-based contracting.
Mar 19, 2018
Steve Cottrell assesses the risks of lapses in pharma's supply chain visibility and outlines what can be done to minimize them
Mar 19, 2018
Pharmaceutical Executive
Amid contrasting views on the success of the now well-established system of outcomes-based agreements in Italy, further demands on global healthcare budgets will likely point to their adoption on a wider scale.
Mar 16, 2018
Pharmaceutical Executive
Outcomes-based contracting could be a potential game-changer in linking drug cost with value, boosting healthcare efficiency, and ensuring that appropriate patients benefit from innovative medicines. But several complex challenges remain in the bid to make this model a mainstay.
Mar 07, 2018
Pharmaceutical Executive
Markus Warmuth, CEO of cancer genomics company H3 Biomedicine, speaks with Pharm Exec about being part of a new wave of biotech business leaders, who let the science chart the course.
Mar 07, 2018
Pharmaceutical Executive
How one pharma vet helped create the first industry-wide training standards for aspiring medical affairs professionals. 
Mar 06, 2018
Pharmaceutical Executive
Drawing from implementation lessons and successes in other industries, possible strategy shifts to pharma’s pricing playbook are explored.
Mar 01, 2018
Jin Zhang outlines four key areas that impacted Chinese pharma in 2017 and looks at how their effects will shape the industry in the years ahead.
Feb 20, 2018
Scott Beauchamp discussed the future of analytics in the life sciences industry—and look at how peers in other industries have reaped the benefits of being early movers.
native1_300x100
lorem ipsum